# Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors

> **NCT02675491** · PHASE1 · COMPLETED · sponsor: **Daiichi Sankyo Co., Ltd.** · enrollment: 15 (actual)

## Conditions studied

- Advanced Solid Malignant Tumors

## Interventions

- **DRUG:** DS-6051b

## Key facts

- **NCT ID:** NCT02675491
- **Lead sponsor:** Daiichi Sankyo Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-10
- **Primary completion:** 2021-12-27
- **Final completion:** 2021-12-28
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02675491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02675491, "Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02675491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*